Name: A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer
Description: The purpose of this study is to determine appropriate dosing of Albumin-bound Rapamycin and evaluate its safety and anti-tumor activity in the treatment of non-muscle invasive bladder cancer.
Status: Phase 1 is closed for recruitment. Recruitment for Phase 2 to begin soon.
Contact Info: 212-305-6665; firstname.lastname@example.org
Name: A Prospective, Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients With Bladder Cancer
Description: The purpose of this study is to investigate if blue light cystoscopy with Cysview improves detection of tumors in patients with bladder cancer during surveillance cystoscopy, using the KARL STORZ D-Light C PDD Flexible Videoscope System. Another purpose is to investigate if Cysview and blue light is safe and effective when used repeatedly.
Status: Recruitment to begin shortly.
Contact Info: 212-932-4309; email@example.com
Name: Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
Description: A combined phase I trial to assess the safety, toxicity, and efﬁcacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
Status: Open for recruitment
Contact Info: 212-305-5526; firstname.lastname@example.org
Name: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Description: An international, phase 3, randomized study to evaluate the efficacy and safety of enzalutamide plus leuprolide, enzalutamide monotherapy, and placebo plus leuprolide in approximately 1860 men with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
Status: open for recruitment
Contact Info: 212-305-6408